Zacks.com on MSN2h
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase IIINovo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...
In December, Merck signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback